Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arteris, Inc. filings document a semiconductor technology business built around System IP for SoC and chiplet design. Its 8-K reports cover quarterly and annual operating results, financial-condition updates, guidance exhibits, customer shipment milestones, royalty trends and product portfolio disclosures for network-on-chip interconnect IP, SoC integration automation software and hardware security assurance.
The company’s proxy materials cover board elections, executive compensation, equity incentive arrangements and stockholder voting matters. They also describe governance and business context for Arteris’ markets, including automotive, artificial intelligence and machine learning, 5G communications, data centers, edge computing, enterprise and consumer electronics.
Arteris, Inc. director Antonio J. Viana reported indirect sales and gifts of Common Stock. On June 4, 2026, the Viana Family Trust, for which he is trustee, executed open-market sales totaling 20,839 shares of Arteris Common Stock in three blocks: 8,939 shares at a weighted average price of $37.089, 7,000 shares at $36.5082, and 4,900 shares at $35.4661, under a Rule 10b5-1 trading plan adopted on June 10, 2025. The filing also reports bona fide gifts totaling 41,678 shares, split between indirect trust holdings and his direct holdings, at a reported price of $0. Following these transactions, Viana reports 85,459 shares held indirectly through the Viana Family Trust and 4,704 shares held directly.
Arteris, Inc. director Joachim Kunkel received an equity grant of 4,703 shares of common stock in the form of restricted stock units (RSUs) as board compensation. The award carried no cash exercise price and increased his directly held position to 74,330 shares.
The 4,703 RSUs each represent a contingent right to one share of common stock and will vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, as long as he continues serving on the board. The grant was based on the average trading price of Arteris stock of $31.89 over the April 21, 2026 to June 2, 2026 period, and Kunkel elected to defer receipt of the shares.
Viana Antonio J reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Antonio J. Viana reported an equity grant of 4,703 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in full on the earlier of the first anniversary of the grant date or immediately before the next annual stockholder meeting, conditioned on his continued board service.
The grant was made on June 2, 2026, based on an average trading price of $31.89 for Arteris stock from April 21, 2026 through June 2, 2026. Following the grant, Viana holds 25,543 shares directly, including these RSUs, and 64,620 shares indirectly through the Viana Family Trust.
Munce Claudia F. reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Claudia F. Munce received an equity grant of 4,703 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, if she continues serving on the board. The grant value was based on the average trading price of $31.89 over the period from April 21, 2026 through June 2, 2026. Following this award, she holds a total of 106,414 common shares directly, and has elected to defer receipt of the shares underlying this RSU grant.
Chitkara Raman reported acquisition or exercise transactions in this Form 4 filing.
Arteris director Raman Chitkara reported an equity award of 4,703 shares of common stock in the form of restricted stock units (RSUs). The RSUs were granted at no cash cost and will vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, contingent on continued Board service. Following this award, Chitkara directly holds 147,570 shares, and has elected to defer receipt of the underlying shares once the RSUs vest.
Cantwell Wayne C reported acquisition or exercise transactions in this Form 4 filing.
Arteris, Inc. director Wayne C. Cantwell reported a compensation-related equity grant in common stock. He received 7,839 restricted stock units (RSUs), each representing one share of Arteris common stock. The RSUs vest in full on the earlier of the first anniversary of the June 2, 2026 grant date or immediately before the next annual stockholder meeting, subject to his continued board service.
After this grant, Cantwell holds 42,571 shares directly. He also has indirect holdings of 189,698 shares through The Cantwell Living Trust, where he serves as trustee, and 38,761 shares through the Decathlon Capital Management 401K Plan FBO Wayne Cantwell. The grant was based on an average Arteris trading price of $31.89 over the period from April 21, 2026 through June 2, 2026, and the RSUs have no expiration date.
Arteris, Inc. director Saiyed Atiq Raza, through a revocable trust for which he serves as trustee, reported multiple stock transactions in the company’s common shares. On June 3, 2026, the trust sold a total of 20,839 shares in open‑market trades at weighted average prices of $37.1294, $38.4583 and $37.6541 per share, under a pre‑arranged Rule 10b5‑1 trading plan.
The filing also shows bona fide gifts totaling 41,678 shares and a separate grant of 4,703 restricted stock units on June 2, 2026, which vest on the earlier of the first anniversary of the grant or the next annual stockholder meeting. Following these moves, the trust holds 160,839 shares and Raza’s direct holdings consist of 4,703 RSUs.
Arteris, Inc. held its annual stockholder meeting on June 2, 2026. Stockholders voted on electing three Class II directors and ratifying the company’s independent auditor. As of the April 9, 2026 record date, 46,092,618 shares of common stock were entitled to vote.
Antonio J. Viana, Wayne C. Cantwell, and Joachim Kunkel were each elected as Class II directors to serve until the 2029 annual meeting or until a successor is elected. Stockholders also ratified the selection of Deloitte & Touche LLP as Arteris’ independent registered public accounting firm for the fiscal year ending December 31, 2026, with 36,095,687 votes cast in favor.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported option exercises and related share sales in Common Stock. On June 1, 2026, he sold 11,504 shares at a weighted average price of $35.9848 and 998 shares at a weighted average price of $36.3895 in open-market transactions, totaling 12,502 shares sold.
These sales were made pursuant to a Rule 10b5-1 trading plan adopted on February 23, 2026. On the same date, he exercised options for 4,000 shares at an exercise price of $0.5600 and 2,500 shares at an exercise price of $9.2800, acquiring 6,500 shares through derivative exercises.
Following the transactions, Alpern held 80,384 to 92,886 shares of Common Stock directly, depending on the specific line item, and retained 61,000 incentive stock options and 27,500 non-qualified stock options with expiration dates in 2029 and 2035, respectively.
Arteris, Inc. director Saiyed Atiq Raza reported open‑market sales of Arteris common stock made through a family trust under a pre‑arranged Rule 10b5‑1 trading plan. On June 1, 2026, the Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust sold 70,000 shares in two transactions at weighted average prices of about $35.99 and $36.45 per share.
These transactions were executed in multiple trades within stated price ranges, and the filing notes that detailed trade breakdowns are available on request. After the reported activity, Raza also shows a separate direct holding of 20,839 Arteris shares.